133 related articles for article (PubMed ID: 25557064)
1. Histone deacetylase inhibitor for NUT midline carcinoma.
Maher OM; Christensen AM; Yedururi S; Bell D; Tarek N
Pediatr Blood Cancer; 2015 Apr; 62(4):715-7. PubMed ID: 25557064
[TBL] [Abstract][Full Text] [Related]
2. Midline carcinoma expressing NUT in malignant effusion cytology.
Shenoy KD; Stanzione N; Caron JE; Fishbein GA; Abtin F; Lluri G; Hirschowitz SL
Diagn Cytopathol; 2019 Jun; 47(6):594-598. PubMed ID: 30734527
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Schwartz BE; Hofer MD; Lemieux ME; Bauer DE; Cameron MJ; West NH; Agoston ES; Reynoird N; Khochbin S; Ince TA; Christie A; Janeway KA; Vargas SO; Perez-Atayde AR; Aster JC; Sallan SE; Kung AL; Bradner JE; French CA
Cancer Res; 2011 Apr; 71(7):2686-96. PubMed ID: 21447744
[TBL] [Abstract][Full Text] [Related]
4. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
[TBL] [Abstract][Full Text] [Related]
6. NUT midline carcinoma of the head and neck: current perspectives.
Napolitano M; Venturelli M; Molinaro E; Toss A
Onco Targets Ther; 2019; 12():3235-3244. PubMed ID: 31118674
[No Abstract] [Full Text] [Related]
7. A rare Japanese case with a NUT midline carcinoma in the nasal cavity: a case report with immunohistochemical and genetic analyses.
Suzuki S; Kurabe N; Minato H; Ohkubo A; Ohnishi I; Tanioka F; Sugimura H
Pathol Res Pract; 2014 Jun; 210(6):383-8. PubMed ID: 24655834
[TBL] [Abstract][Full Text] [Related]
8. HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.
Esteves G; Ferreira J; Afonso R; Martins C; Zagalo C; Félix A
Head Neck Pathol; 2020 Dec; 14(4):1117-1122. PubMed ID: 31989434
[TBL] [Abstract][Full Text] [Related]
9. Primary pulmonary NUT midline carcinoma: An elusive and a rare diagnostic entity.
Pasricha S; Jajodia A; Sharma A; Bansal D; Batra U; Gupta G; Durga G; Kamboj M; Nathany S; Mehta A
J Cancer Res Ther; 2023; 19(3):816-818. PubMed ID: 37470617
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
[TBL] [Abstract][Full Text] [Related]
11. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review.
Nakamura H; Tsuta K; Tsuda H; Katsuya Y; Naka G; Iizuka T; Igari T
Pathol Res Pract; 2015 Jan; 211(1):92-8. PubMed ID: 25433996
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Protein in Testis Carcinoma of the Thorax.
Maruyama N; Hikiishi A; Suginaka M; Furukawa K; Ogawa K; Nakamura N; Yoshida Y; Takata M; Nishijima M; Otani K; Kamimori T; Fujiwara H; Yoshimatsu Y; Ueda K
Intern Med; 2018 Nov; 57(21):3169-3173. PubMed ID: 29877266
[TBL] [Abstract][Full Text] [Related]
13. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy.
Engleson J; Soller M; Panagopoulos I; Dahlén A; Dictor M; Jerkeman M
BMC Cancer; 2006 Mar; 6():69. PubMed ID: 16542442
[TBL] [Abstract][Full Text] [Related]
14. BRD4-NUT carcinoma of the mediastinum in a pediatric patient: multidetector computed tomography imaging findings.
Nelson BA; Lee EY; French CA; Bauer DE; Vargas SO
J Thorac Imaging; 2010 Aug; 25(3):W93-6. PubMed ID: 20395873
[TBL] [Abstract][Full Text] [Related]
15. NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement.
Zhang H; Kong W; Liang W
Evid Based Complement Alternat Med; 2022; 2022():3369895. PubMed ID: 35832518
[TBL] [Abstract][Full Text] [Related]
16. NUT Midline Carcinoma: A Series of Five Cases, Including One with Unusual Clinical Course.
Kakkar A; Antony VM; Irugu DVK; Adhikari N; Jain D
Head Neck Pathol; 2018 Jun; 12(2):230-236. PubMed ID: 28948459
[TBL] [Abstract][Full Text] [Related]
17. Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.
Zhang Y; Han K; Dong X; Hou Q; Li T; Li L; Zhou G; Liu X; Zhao G; Li W
Front Oncol; 2021; 11():700781. PubMed ID: 34527578
[TBL] [Abstract][Full Text] [Related]
18. NUT midline carcinoma: an aggressive intrathoracic neoplasm.
Parikh SA; French CA; Costello BA; Marks RS; Dronca RS; Nerby CL; Roden AC; Peddareddigari VG; Hilton J; Shapiro GI; Molina JR
J Thorac Oncol; 2013 Oct; 8(10):1335-8. PubMed ID: 24457244
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
